First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Zaawansowany nowotwór (przerzuty lub niemożliwy do usunięcia chirurgicznie) - sarczyna, czerniak, rak płuca lub rak pęcherza
- •Nowotwór, który nie reaguje na standardowe leczenie lub pacjent jest na niego alergiczny
- •Określony typ białka HLA w komórkach (HLA-A*02:01 lub pokrewne)
- •Widoczny nowotwór na badaniach (CT lub MRI)
- •Możliwość dostarczenia próbki tkanki nowotworowej
- •Dobry ogólny stan zdrowia (wynik ECOG 0 lub 1)
- •Prawidłowe wyniki badań krwi i funkcja nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Dana-Farber Cancer Institute
Boston, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
Sarah Cannon Research Institute
Nashville, United States
UZ Leuven Europe Leuven
Leuven, Belgium
Centre Leon Berard
Lyon, France
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
Amsterdam, Netherlands
Seoul National University Hospital
Seoul, South Korea
Trial contact
Contact for Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.